HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (āSerinaā) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platformā¢ drug optimization technology, today announced its financial results for the second quarter ended JuneĀ 30, 2025, along with key recent updates.
Related Questions
How did Serina Therapeutics' Q2 2025 revenue and net loss compare to the same quarter last year?
What guidance did the company provide for Q3 2025 and full-year 2025 financial performance?
What is the current cash runway and burn rate, and when does the company anticipate needing additional financing?
What milestones were achieved for the lead IND candidate SER-252, and what is the timeline for IND filing or FDA interactions?
How does SER-252's progress compare to other advanced Parkinson's disease therapies in development?
What are the details of the recent partnership or licensing agreements mentioned in the highlights?
How does the company's valuation (P/E, EV/EBITDA, price/ cash) compare to peers in the biotech/ Parkinson's space?
How does the sentiment score of 30 affect market perception, and what is the analyst consensus on the stock?
What risk factors (e.g., clinical trial outcomes, regulatory hurdles, competition) could materially affect the company's outlook?
What is the market potential and competitive landscape for a therapy targeting advanced Parkinson's disease?
Are there any upcoming catalysts (e.g., trial data, regulatory decisions, conference presentations) that could drive the stock price?
What is the breakdown of R&D versus SG&A expenses, and are there any costāsaving initiatives underway?